Cetuximab, a chimeric immunoglobulin G1 (IgG1) antibody against EGFR, is approved for use in conjunction with radiotherapy in locoregionally advanced SCCHN or as a single regimen in platinum-refractory, recurrent/metastatic SCCHN [13, 14]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.